In the last trading session, 6.33 million shares of the Dermata Therapeutics Inc (NASDAQ:DRMA) were traded, and its beta was 0.78. Most recently the company’s share price was $1.44, and it changed around $0.23 or 19.01% from the last close, which brings the market valuation of the company to $3.50M. DRMA currently trades at a discount to its 52-week high of $13.35, offering almost -827.08% off that amount. The share price’s 52-week low was $1.05, which indicates that the current value has risen by an impressive 27.08% since then. We note from Dermata Therapeutics Inc’s average daily trading volume that its 10-day average is 0.75 million shares, with the 3-month average coming to 529.88K.
Dermata Therapeutics Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended DRMA as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Dermata Therapeutics Inc is expected to report earnings per share of 0 for the current quarter.
Dermata Therapeutics Inc (NASDAQ:DRMA) trade information
Instantly DRMA has showed a green trend with a performance of 19.01% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 1.4500 on recent trading dayincreased the stock’s daily price by 0.69%. The company’s shares are currently down -84.26% year-to-date, but still up 27.63% over the last five days. On the other hand, Dermata Therapeutics Inc (NASDAQ:DRMA) is 6.67% up in the 30-day period. We can see from the shorts that 93737.0 shares have been sold at a short interest cover period of 0.52 day(s).
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 76.0% from its current value. Analyst projections state that DRMA is forecast to be at a low of $6 and a high of $6.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 26.37%.
DRMA Dividends
Dermata Therapeutics Inc’s next quarterly earnings report is expected to be released in January.
Dermata Therapeutics Inc (NASDAQ:DRMA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.84% of Dermata Therapeutics Inc shares, and 0.66% of them are in the hands of institutional investors. The stock currently has a share float of 0.67%.
